Lead Product(s) : Dextromethorphan Hydrobromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Mucinex Children's Launches Mighty Chews
Details : Mighty Chews consisting, Dextromethorphan HBr, is the first and only over-the-counter medicated children's soft chew for cough relief.
Product Name : Mighty Chews
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 30, 2024
Lead Product(s) : Dextromethorphan Hydrobromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Promethazine Hydrochloride,Dextromethorphan Hydrobromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ANI Pharmaceuticals Launches Oral Solution For Cough And Allergy Relief
Details : Promethazine HCl and Dextromethorphan Hydrobromide-Generic is an approved oral solution, which is indicated for the patients suffering from cough.
Product Name : Promethazine HCl-Dextromethorphan HBr-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 13, 2024
Lead Product(s) : Promethazine Hydrochloride,Dextromethorphan Hydrobromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brompheniramine Maleate,Dextromethorphan Hydrobromide,Phenylephrine Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Foundation Consumer Healthcare
Deal Size : Undisclosed
Deal Type : Agreement
Details : This diverse portfolio of products includes Breathe Right® Nasal Strips, the world’s #1 nasal strip, and Children’s Dimetapp®, the #1 pharmacist-recommended brand for children's cough and cold products, as well as Anbesol®, Alavert®, Dristan®, P...
Product Name : Dimetapp
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 16, 2020
Lead Product(s) : Brompheniramine Maleate,Dextromethorphan Hydrobromide,Phenylephrine Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Foundation Consumer Healthcare
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Dextromethorphan Hydrobromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dextromethorphan Pediatric Acute Cough Study
Details : Dextromethorphan HBr is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cough.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 08, 2016
Lead Product(s) : Dextromethorphan Hydrobromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dextromethorphan Hydrobromide
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dextromethorphan HBr is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pseudobulbar Palsy.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 14, 2015
Lead Product(s) : Dextromethorphan Hydrobromide
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dextromethorphan Hydrobromide
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : TSH Biopharm Corporation Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy Study of Dextromethorphan to Treat Rheumatoid Arthritis
Details : Dextromethorphan HBr is a Controlled Substance drug candidate, which is currently being evaluated in clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 20, 2015
Lead Product(s) : Dextromethorphan Hydrobromide
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : TSH Biopharm Corporation Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dextromethorphan Hydrobromide
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nuedexta for the Treatment of Adults With Autism
Details : Dextromethorphan HBr is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Autistic Disorder.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 28, 2012
Lead Product(s) : Dextromethorphan Hydrobromide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dextromethorphan Hydrobromide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Heinrich-Heine University, Duesseldorf
Deal Size : Inapplicable
Deal Type : Inapplicable
Dextromethorphan, Amantadine and Glucose Homeostasis in Diabetes Subjects
Details : Dextromethorphan HBr is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 28, 2011
Lead Product(s) : Dextromethorphan Hydrobromide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Heinrich-Heine University, Duesseldorf
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dextromethorphan Hydrobromide
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : The Emmes Company, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Dextromethorphan for Diabetic Macular Edema
Details : Dextromethorphan HBr is a Controlled Substance drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Macular Edema.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 27, 2011
Lead Product(s) : Dextromethorphan Hydrobromide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : The Emmes Company, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
